Hepatology:绝经后妇女循环性类固醇激素的浓度与肝癌之间的关联

2020-09-09 MedSci原创 MedSci原创

在几乎所有国家,男性肝癌(LC)的发病率均比女性高100%-200%。但是,这种差异主要是由肝细胞癌(HCC)驱动的,其占肝癌病例的75%,肝内胆管癌(ICC)占病例的12%,男性的比率仅高30%。

背景及目的:

在几乎所有国家,男性肝癌(LC)的发病率均比女性高100%-200%。但是,这种差异主要是由肝细胞癌(HCC)驱动的,其占肝癌病例的75%,肝内胆管癌(ICC)占病例的12%,男性的比率仅高30%。本项研究假定激素是性别差异的基础,研究人员通过调查诊断前的循环激素和性激素结合球蛋白(SHBG)水平来判断是否与LC风险相关。

 

方法与结果:

研究人员使用气相色谱/串联质谱法和竞争性电化学发光免疫分析法分别从191名绝经后女性LC患者(HCC,n = 83; ICC,n = 56)和426个对照组的基线血清/血浆样品中定量了7种性甾体激素和性激素结合球蛋白(SHBG)。然后对所有患者的激素水平与肝癌的发生情况进行了统计分析。

 

 

结果:

研究结果显示4-雄烯二酮(4-二酮)的浓度增加一倍可降低50%的LC风险(OR = 0.50; 95%CI = 0.30-0.82),而SHBG升高则可提高31%的风险(OR = 1.31; 95%CI = 1.05-1.63)。检查组织学,雌二醇加倍与ICC风险增加40%有关(OR = 1.40; 95%CI = 1.05-1.89),但与HCC无关(OR = 1.12; 95%CI = 0.81-1.54)。

              图:类固醇激素代谢途径

 

结论:

这项研究提供的证据表明,较高的4-二酮水平可能与较低的女性SHBG和较高的LC风险有关,因此女性类固醇激素-雌二醇可能与ICC风险增加有关。

 

原始出处:

Jessica L. Petrick. Et al. Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Postmenopausal Women. Hepatology.2020.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1954588, encodeId=c42a1954588a6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat May 22 13:08:11 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257253, encodeId=e915125e25307, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313459, encodeId=4b0a131345994, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332022, encodeId=df4e13320228d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427454, encodeId=bb2f142e454d8, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544661, encodeId=0554154466197, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631637, encodeId=915b163163ea6, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040315, encodeId=ec9410403156f, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Sep 09 22:08:11 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883963, encodeId=cf4688396394, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 09 20:15:53 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883952, encodeId=e97e883952dc, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Wed Sep 09 19:34:39 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1954588, encodeId=c42a1954588a6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat May 22 13:08:11 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257253, encodeId=e915125e25307, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313459, encodeId=4b0a131345994, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332022, encodeId=df4e13320228d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427454, encodeId=bb2f142e454d8, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544661, encodeId=0554154466197, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631637, encodeId=915b163163ea6, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040315, encodeId=ec9410403156f, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Sep 09 22:08:11 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883963, encodeId=cf4688396394, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 09 20:15:53 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883952, encodeId=e97e883952dc, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Wed Sep 09 19:34:39 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1954588, encodeId=c42a1954588a6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat May 22 13:08:11 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257253, encodeId=e915125e25307, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313459, encodeId=4b0a131345994, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332022, encodeId=df4e13320228d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427454, encodeId=bb2f142e454d8, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544661, encodeId=0554154466197, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631637, encodeId=915b163163ea6, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040315, encodeId=ec9410403156f, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Sep 09 22:08:11 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883963, encodeId=cf4688396394, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 09 20:15:53 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883952, encodeId=e97e883952dc, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Wed Sep 09 19:34:39 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1954588, encodeId=c42a1954588a6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat May 22 13:08:11 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257253, encodeId=e915125e25307, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313459, encodeId=4b0a131345994, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332022, encodeId=df4e13320228d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427454, encodeId=bb2f142e454d8, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544661, encodeId=0554154466197, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631637, encodeId=915b163163ea6, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040315, encodeId=ec9410403156f, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Sep 09 22:08:11 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883963, encodeId=cf4688396394, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 09 20:15:53 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883952, encodeId=e97e883952dc, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Wed Sep 09 19:34:39 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1954588, encodeId=c42a1954588a6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat May 22 13:08:11 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257253, encodeId=e915125e25307, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313459, encodeId=4b0a131345994, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332022, encodeId=df4e13320228d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427454, encodeId=bb2f142e454d8, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544661, encodeId=0554154466197, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631637, encodeId=915b163163ea6, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040315, encodeId=ec9410403156f, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Sep 09 22:08:11 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883963, encodeId=cf4688396394, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 09 20:15:53 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883952, encodeId=e97e883952dc, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Wed Sep 09 19:34:39 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
    2020-09-11 gwc384
  6. [GetPortalCommentsPageByObjectIdResponse(id=1954588, encodeId=c42a1954588a6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat May 22 13:08:11 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257253, encodeId=e915125e25307, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313459, encodeId=4b0a131345994, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332022, encodeId=df4e13320228d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427454, encodeId=bb2f142e454d8, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544661, encodeId=0554154466197, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631637, encodeId=915b163163ea6, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040315, encodeId=ec9410403156f, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Sep 09 22:08:11 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883963, encodeId=cf4688396394, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 09 20:15:53 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883952, encodeId=e97e883952dc, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Wed Sep 09 19:34:39 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1954588, encodeId=c42a1954588a6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat May 22 13:08:11 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257253, encodeId=e915125e25307, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313459, encodeId=4b0a131345994, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332022, encodeId=df4e13320228d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427454, encodeId=bb2f142e454d8, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544661, encodeId=0554154466197, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631637, encodeId=915b163163ea6, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040315, encodeId=ec9410403156f, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Sep 09 22:08:11 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883963, encodeId=cf4688396394, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 09 20:15:53 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883952, encodeId=e97e883952dc, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Wed Sep 09 19:34:39 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
    2020-09-11 zxxiang
  8. [GetPortalCommentsPageByObjectIdResponse(id=1954588, encodeId=c42a1954588a6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat May 22 13:08:11 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257253, encodeId=e915125e25307, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313459, encodeId=4b0a131345994, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332022, encodeId=df4e13320228d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427454, encodeId=bb2f142e454d8, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544661, encodeId=0554154466197, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631637, encodeId=915b163163ea6, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040315, encodeId=ec9410403156f, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Sep 09 22:08:11 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883963, encodeId=cf4688396394, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 09 20:15:53 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883952, encodeId=e97e883952dc, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Wed Sep 09 19:34:39 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
    2020-09-09 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1954588, encodeId=c42a1954588a6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat May 22 13:08:11 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257253, encodeId=e915125e25307, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313459, encodeId=4b0a131345994, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332022, encodeId=df4e13320228d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427454, encodeId=bb2f142e454d8, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544661, encodeId=0554154466197, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631637, encodeId=915b163163ea6, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040315, encodeId=ec9410403156f, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Sep 09 22:08:11 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883963, encodeId=cf4688396394, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 09 20:15:53 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883952, encodeId=e97e883952dc, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Wed Sep 09 19:34:39 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
    2020-09-09 医鸣惊人

    学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1954588, encodeId=c42a1954588a6, content=<a href='/topic/show?id=cb1de613583' target=_blank style='color:#2F92EE;'>#类固醇激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76135, encryptionId=cb1de613583, topicName=类固醇激素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat May 22 13:08:11 CST 2021, time=2021-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257253, encodeId=e915125e25307, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313459, encodeId=4b0a131345994, content=<a href='/topic/show?id=d59be61251d' target=_blank style='color:#2F92EE;'>#类固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76125, encryptionId=d59be61251d, topicName=类固醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332022, encodeId=df4e13320228d, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427454, encodeId=bb2f142e454d8, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544661, encodeId=0554154466197, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631637, encodeId=915b163163ea6, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Fri Sep 11 10:08:11 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040315, encodeId=ec9410403156f, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Wed Sep 09 22:08:11 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883963, encodeId=cf4688396394, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Wed Sep 09 20:15:53 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883952, encodeId=e97e883952dc, content=阅读, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3282551952, createdName=12543f43m99暂无昵称, createdTime=Wed Sep 09 19:34:39 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
    2020-09-09 12543f43m99暂无昵称

    阅读

    0

相关威廉亚洲官网

肝癌成中国第二大肿瘤致死病因 早筛情况不理想

肝癌是中国第二大肿瘤致死病因,近年来国内每年因肝癌死亡人数达数十万……16日,在北京举行的了“肝癌早诊早筛云端论坛”上,业内专家透露了这样一组数据。与数据形成对比的是,中国尚未普及肝癌早诊早筛。如何应

J Hepatol:侯金林教授团队发表全球跨病因和跨种族的慢性肝病患者肝癌风险预测模型——aMAP评分

最近来自南方医院肝病中心的侯金林教授领衔的全球大规模临床研究在顶级期刊《Journal of Hepatology》上发表,该研究发现了新的肝癌风险预测模型——aMAP评分,这

Nat Commun :肝细胞核因子4A调节含硫氨基酸代谢并决定肝癌对甲硫氨酸限制的敏感性

含硫氨基酸代谢在肝癌中失调意味着甲硫氨酸限制有可能成为潜在肝癌治疗手段,但目前对这种失调的分子机制并不了解,甲硫氨酸限制是否可以用于肝癌治疗或增加现有疗法的敏感性值得探索。

蒽环类药物在不同恶性肿瘤中的应用价值

蒽环类药物在肿瘤内科治疗中广泛应用,是具有代表性的细胞毒类药物。过去几十年中,虽然靶向药物、免疫治疗药物等为肿瘤治疗带来了新的突破,但是蒽环类药物仍然在乳腺癌、肝癌等很多实体肿瘤和多发性骨髓瘤(MM)

Hepatology:25-羟维生素D的血清的生物利用度而不是总水平与肝细胞癌的生存率有关

肝癌是全球第六大癌症和第四大癌症死因,尽管在现代治疗时代已观察到存活率提高,但肝癌的仍然是一般无法治愈的。

Br J Cancer:Galectin-3激活β-catenin信号通路促进肝癌转移

肝细胞癌(HCC)作为最常见的癌症之一,是全球第二大癌症相关死亡原因,在中国约有50%的病例和死亡发生。尽管目前对于该疾病的治疗策略有所改善,但由于其高的转移性也限制了患者的长期存活率。